On January 5, 2022 Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, reported that the Company will participate in three investor conferences during the month of January (Press release, Portage Biotech, JAN 5, 2022, View Source [SID1234598306]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of the Company’s participation, CEO Dr. Ian Walters will join other thought leaders in the oncology space two panel discussions on next-generation immuno-oncology therapies and the future of immuno-oncology at the LifeSci Partners 11th Annual Corporate Access Event and the H.C. Wainwright BioConnect Conference, respectively, and will also join a fireside chat discussion at the B. Riley Securities’ 2022 Oncology Conference.

Registration and other details for each event are as follows:

11th Annual LifeSci Partners Corporate Access Event
Date: January 5-7, 2022
Format: 1-on-1 investor meetings
Panel Discussion:
Next Gen Immune-Oncology Panel
January 7, 2022 at 7:30am ET
Registration – View Source

H.C. Wainwright BioConnect Conference
Date: January 10-13, 2022
Format: 1-on-1 investor meetings; on demand pre-recorded presentation available through conference portal
Panel Discussion:
New Directions in Immuno-Oncology

B. Riley Securities’ Oncology Investor Conference
Date: January 27-28, 2022
Format: Fireside chat January 28, 2022